Skip to main content

Table 5 Results of pulmonary function tests and respiratory muscle strength among COVID-19 patients between glucocorticoid group and the regular groups

From: Impact of coronavirus disease 2019 on pulmonary function in early convalescence phase

Parameter All patients (n=57) GC group (n=16) Regular group (n=41) p Value
FVC (% of predicted) 100.96 (15.93) 97.25 (18.69) 102.40 (14.72) 0.414
FEV1 (% of predicted) 97.89 (14.91) 94.35 (15.40) 99.27 (14.68) 0.279
FEV1 / FVC (%) 81.22 (6.13) 80.74 (4.68) 81.40 (6.65) 0.804
TLC (% of predicted) 93.94 (12.75) 90.15 (16.01) 95.45 (11.06) 0.323
RV (% of predicted) 90.68 (28.08) 85.49 (19.01) 92.76 (30.95) 0.593
DLCO (% of predicted 78.38 (13.59) 74.67 (14.37) 79.78 (13.20) 0.657
Raw (% of predicted) 105.38 (31.38) 96.02 (25.81) 109.22 (32.93) 0.214
R5 (% of predicted) 126.64 (29.45) 119.66 (30.62) 129.37 (28.91) 0.127
R20 (% of predicted) 132.76 (30.95) 123.51 (31.99) 136.37 (30.15) 0.106
Pimax (% of predicted) 76.16 (24.28) 85.21 (26.54) 72.53 (22.65) 0.059
Pemax (% of predicted) 102.73 (32.68) 104.22 (28.03) 102.14 (34.68) 0.479
  1. Values given as % predicted, unless otherwise indicated
  2. GC glucocorticoid